Skip to main content
SpringerLink
Log in

Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Pharmacokinetic drug-drug interactions influence drug efficacy, tolerability, and compliance. Such interactions are both more common and of more clinical relevance than often appreciated. The US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products have recently issued guidelines setting out in vitro and in vivo investigations to be conducted during drug development. These guidelines reflect the increasing interest of public health authorities in this topic.

Cerivastatin is a novel, potent HMG-CoA reductase inhibitor that effectively reduces serum cholesterol levels at low daily doses. It is completely absorbed after oral administration, undergoes moderate first-pass metabolism and high plasma protein binding, and is cleared exclusively via hepatic cytochrome P450 (CYP). Unlike other drugs of its class, cerivastatin has a dual metabolic pathway, with the involvement of more than one CYP isozyme. Metabolites are cleared via both biliary and renal excretion.

On the basis of this pharmacokinetic profile and a knowledge of the target population, the formal in vivo interaction programme for cerivastatin investigated many important potential cerivastatin drug-drug interactions. Cerivastatin appears to lack clinically relevant interactions with digoxin, warfarin, antacid, cimetidine, nifedipine, omeprazole, erythromycin and itraconazole.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. European Agency for the Evaluation of Medicinal Products (EMEA), Human Medicines Evaluation Unit. CPMP note for guidance on the investigation of drug interactions: CPMP/EWP/560/ 95. London: EMEA, Jun 1998

    Google Scholar 

  2. Grönroos PE, Irjala KM, Huupponen RK, et al. A medication database — a tool for detecting drug interactions in hospital. Eur J Clin Pharmacol 1997; 53: 13–7

    Article  PubMed  Google Scholar 

  3. Stockley IH. Drug interactions. 2nd ed. Oxford: Blackwell Scientific Publications, 1991

    Google Scholar 

  4. Garnett WR. Interactions with hydroxymethylglutaryl-coenzmye A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639–45

    PubMed  CAS  Google Scholar 

  5. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzmye A reductase inhibitors. Clin Pharmacokinet 1996; 31: 348–71

    Article  PubMed  CAS  Google Scholar 

  6. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors — similarities and differences. Clin Pharmacokinet 1997; 32: 403–25

    Article  PubMed  Google Scholar 

  7. US Food and Drug Administration (FDA). Guidance for industry: drug metabolism/drug interaction studies in the drug development process: studies in vitro. Rockville; FDA, Apr 1997

  8. Angerbauer R, Bischoff H, Steinke W, et al. BAYw 6228. Drugs Future 1994; 19: 537–41

    Google Scholar 

  9. Bischoff H, Angerbauer R, Bender J, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997; 135: 119–30

    Article  PubMed  CAS  Google Scholar 

  10. Stein E, Sprecher D, Allenby KS, et al. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0.2mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997; 2: 7–16

    Article  PubMed  CAS  Google Scholar 

  11. Stein EA. Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. Drugs 1998; 56 Suppl. 1: 25–32

    Article  Google Scholar 

  12. Mück W, Ritter W, Dietrich H, et al. Influence of the antacid Maalox® and the Fb-antagonist cimetidine on the pharmaco-kinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 261–4

    PubMed  Google Scholar 

  13. Ritter W, Frey R, Krol G, et al. Single dose pharmacokinetics of rivastatin, a novel HMG-CoA redcutase inhibitor. Naunyn Schmiedebergs Arch Pharmacol 1993; 347 Suppl.: R39

    Google Scholar 

  14. Ritter W, Frey R, Krol G, et al. Rivastatin single dose pharmacokinetics. Clin Pharmacol Ther 1993; 53: 210

    Google Scholar 

  15. Mazzu A, Lettieri J, Kaiser L, et al. Ascending multiple dose safety, tolerability and pharmacokinetics of rivastatin in humans. Clin Pharmacol Ther 1993; 53: 230

    Google Scholar 

  16. Mazzu A, Lettieri J, Heller AH. Pharmacokinetics of cerivastatin administration with and without food in the morning and evening. Atherosclerosis 1997; 130 Suppl.: S29

    Google Scholar 

  17. Mück W, Ochmann K, Mazzu A, et al. Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor. Atherosclerosis 1997; 134: 130

    Article  Google Scholar 

  18. Lettieri J, Krol G, Mazzu A, et al. Effect of age and gender on steady-state pharmacokinetics of rivastatin. Pharm Res 1993; 10 Suppl.: S338

    Google Scholar 

  19. Azuma J. A clinical trial of pharmacokinetics of BAY w 6228 in elderly volunteers. Jpn Pharmacol Ther 1996; 24 Suppl. 9: 55–66

    Google Scholar 

  20. Stein EA, Isaacsohn J, Zinny M, et al. Pharmacokinetics, safety and tolerability of multiple-dose cerivastatin in males and females: a double-blind study. Atherosclerosis 1997; 130 Suppl.: S33

    Article  Google Scholar 

  21. Mazzu A, Lettieri J, Kaiser L, et al. A multiple-dose study on the safety and pharmacokinetics of cerivastatin in young and elderly male volunteers. Atherosclerosis 1997; 130 Suppl.: S29

    Google Scholar 

  22. Mück W, Kawano K, Unger S, et al. Interethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998. In press

  23. Vormfelde SV, Gleiter CH, Freudenthaler S, et al. Pharmacokinetics of single dose cerivastatin in subjects with normal and impaired renal function. Atherosclerosis 1997; 130 Suppl.: S33

    Article  Google Scholar 

  24. Vormfelde SV, Freudenthaler S, Mück W, et al. Cerivastatin, an inhibitor of the HMG-CoA reductase, has no need for dose adjustment in renal dysfunction. Eur J Clin Pharmacol 1997; 52 Suppl.: A163

    Article  Google Scholar 

  25. Steinke W, Yamashita S, Tabei M, et al. Cerivastatin, a new inhibitor of HMG-CoA reductase. Pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996; 24 Suppl. 9: 1217–37

    Google Scholar 

  26. Mück W, Ritter W, Ochmann K, et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol 1997; 35: 255–60

    Google Scholar 

  27. Boberg M, Angerbauer R, Kanhai W, et al. [14C]BAY w 6228: Biotransformation in human liver microsomes in vitro. Characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997; 25: 321–31

    PubMed  CAS  Google Scholar 

  28. Radtke M, Boberg M, Kanhai W, et al. Cerivastatin: identification of human cytochrome P-450 isozymes involved in the biotransformation of the drug and two active metabolites [abstract no. 217]. Proceedings of the 8th North American ISSX Meeting; 1997 Oct 26–30; Hilton Head, South Carolina: 109

  29. Bischoff H, Angerbauer R, Boberg M, et al. Cerivastatin: high enzyme affinity and active metabolites contribute to its high pharmacological activity. Atherosclerosis 1997; 130 Suppl.: S25

    Article  Google Scholar 

  30. Mück W, Ochmann K, Rohde G, et al. No drug-drug interaction between cerivastatin and omeprazole. Naunyn-Schmie-debergs Arch Pharmacol 1998; 357 Suppl.: R175

    Google Scholar 

  31. Mück W, Ritter W, Frey R, et al. Influence of cholestyramine on the pharmacokinetics of cerivastatin. Int J Clin Pharmacol Ther 1997; 35: 250–4

    PubMed  Google Scholar 

  32. Schall R, Mueller FO, Hundt HK, et al. No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin. J Clin Pharmacol 1995; 35: 306–13

    PubMed  CAS  Google Scholar 

  33. Lettieri J, Krol G, Mazzu A, et al. Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin. Atherosclerosis 1997; 130 Suppl.: S29

    Article  Google Scholar 

  34. Mück W, Ochmann K, Rohde G, et al. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998; 53: 469–73

    Article  PubMed  Google Scholar 

  35. Sachse R, Brendel E, Mück W, et al. No drug-drug interaction between cerivastatin and nifedipine. Naunyn-Schmiedebergs Arch Pharmacol 1998; 357 Suppl.: R174

    Google Scholar 

  36. Mai I, Bauer S, Fritsche J, et al. Clinical pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporine A (CSA) [abstract no. 419]. Eur J Clin Pharmacol 1997; 52 Suppl.: A137

    Google Scholar 

  37. Steinjans VW, Hartmann M, Huber R, et al. Lack of pharmacokinetic interaction as an equivalence problem. J Clin Pharmacol Ther 1991; 29: 323–8

    Google Scholar 

  38. Mück W, Ochmann K, Kuhlmann J. Rationale for pharmacokinetic drug-drug interaction programme within clinical development — case history: cerivastatin, a new HMG-CoA reductase inhibitor. Eur J Clin Pharmacol 1997; 52 Suppl.: A 138.

    Google Scholar 

  39. Spach DH, Bauwens JE, Clark CD, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–5

    PubMed  CAS  Google Scholar 

  40. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664–5

    Article  PubMed  CAS  Google Scholar 

  41. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996; 60: 54–61

    Article  PubMed  CAS  Google Scholar 

  42. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332–41

    Article  PubMed  CAS  Google Scholar 

  43. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1998; 63: 397–402

    Article  PubMed  CAS  Google Scholar 

  44. Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355–61

    CAS  Google Scholar 

  45. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450S. Drug Metab Dispos 1997; 25: 1191–99

    PubMed  CAS  Google Scholar 

  46. von Rosenstiel NA, Adam D. Macrolide antibacterials — drug interactions of clinical significance. Drug Saf 1995; 13: 105–22

    Article  Google Scholar 

  47. Krol GJ, Beck GW, Ritter W, et al. LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993; 11: 1269–75

    Article  PubMed  CAS  Google Scholar 

  48. Ikeda T, Ishigami M, Yamazoe Y. Inhibition of hepatic cytochrome P450 isoform, CYP3A, by 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors. Atherosclerosis 1997; 134: 135

    Article  Google Scholar 

  49. Ulbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1998; 62: 311–21

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bayer AG, Institute of Clinical Pharmacology, Aprather Weg, Building 405/V, D-42096, Bayer AG Wuppertal, Germany

    Wolfgang Mück

Authors
  1. Wolfgang Mück
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mück, W. Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions. Drugs 56 (Suppl 1), 15–23 (1998). https://doi.org/10.2165/00003495-199856001-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199856001-00003

Keywords

Search

Navigation